Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-6204 in Advanced Solid Tumors
NCT06726369Phase 1Recruiting
- Sponsor
- Kelun-Biotech
- Start
- Dec 2024
- Primary completion
- Dec 2029
- Modality
- Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SKB535 in solid tumor, sponsored by Kelun-Biotech. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Events and 1 more. Started Dec 2024; status: recruiting.
02
Drugs
SKB535
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT06726369.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06726369.